SCHEMBL24069067

SCHEMBL24069067

O=S(=O)(NCCN1CCN(Cc2ccccc2)CC1)c1ccc2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 2/20 0.56
▸ GRIN2B Q13224 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ BCHE P06276 1/20 0.45
▸ ACHE P22303 1/20 0.45
▸ KMT2A Q03164 3/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24069064 0.93 HTR7 (0.66) HTR7GRIN2BALDH1A1BCHEACHE
SCHEMBL29022566 0.86 HTR7 (0.56) HTR7SLC6A4
SCHEMBL24070172 0.84 SLC6A2 (0.62) SLC6A2SLC6A4
SCHEMBL24070168 0.82 HTR7 (0.59) HTR7SLC6A4
SCHEMBL24070176 0.82 CARM1 (0.50) HTR7BCHESLC6A2SLC6A4TSHR
SCHEMBL29022565 0.80 HTR7 (0.66) HTR7SLC6A4
SCHEMBL24069077 0.79 HTR7 (0.87) HTR7ALDH1A1KMT2APOLBSMN1; SMN2
SCHEMBL24069430 0.78 SLC6A2 (0.57) HTR7KMT2ASLC6A2SLC6A4MEN1
SCHEMBL29022592 0.76 HTR7 (0.67) HTR7SLC6A4
SCHEMBL24069080 0.76 HTR7 (0.58) HTR7ALDH1A1BCHEACHESLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
WO-2021241875-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS 재단법인 대구경북첨단의료산업진흥재단 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 HTR7 79/4885GRIN2B 429/4885ALDH1A1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback